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ABSTRACT 
HIV/HBV co-infection places patients at high risk of liver-related morbidity and mortality and the interaction of the two 
viruses can further complicate treatment. Pregnant women are especially at high risk for increased morbidity and mortality 
due to infection, and information about HIV/HBV co-infection in pregnant women is scanty. This study examined the 
occurrence of HBV antibodies in HIV-1 positive pregnant women and the relationship to Ante-retroviral therapy (ART) and 
other demographic characteristics.  Blood samples were collected from 135 HIV pregnant positive women who were either 
on ART or Not, from May – June, 2008 at the Jos University Teaching Hospital (JUTH) and the Plateau State Specialist 
Hospital (PSSH). Presence of hepatitis B surface (HBsAg) antigen in serum was determined using Antec strips (Antec 
diagnostics UK) and their immunologic status were determined by measuring the CD4+ counts using SL_3 cyFlow counter 
(Partec, Germany) . Sixteen 16 (11.8%) of the women examined were seropositive for Hepatitis B virus. Occupation was 
significantly associated with the prevalence of the hepatitis co-infection in the population examined (8.8% of house wives 
and 5.5% of business women had co-infection, p<0.05). The immunologic status (CD4+ of most of the HIV/HBV co-infected 
pregnant women (81.5%) was low (below 300 cells/mm3) although all were on Anti retroviral therapy. The 11.8% prevalence 
rate reported in this study confirms the endemicity of HBV /HIV co-infection in Nigeria, and this supports the calls for 
screening for Hepatitis B as a routine in antenatal care. 
 




Of the 33.3 million people currently living with 
HIV/AIDS, 68% reside in sub-Saharan Africa (1). 
HIV/AIDS weakens a person’s ability to fight 
infections; HIV-infected people are three to six 
times more likely to develop a chronic or long-term 
hepatitis B infection because of their weakened 
immune systems than individuals without HIV (2). 
Approximately 5%–10% of HIV-infected persons 
also have chronic HBV infection, defined as testing 
positive for HBsAg for more than 6 months. 
 
An estimated 400 million people are infected with 
Hepatitis B virus (HBV) with the majority of cases 
occurring in regions of Asia and Africa where the 
virus is endemic. In these continents up to 70% of 
adults show serologic evidence of current or prior 
infection and 8 to 15% have chronic HBV infection 
(2). Hepatitis B virus (HBV) is the most common 
cause of serious liver infection; it causes transient 
and chronic infections of the liver. Clinical 
presentation of Hepatitis B ranges from subclinical 
to symptomatic hepatitis and, in rare instances, 
fulminant hepatitis (3). HBV and HIV have common 
characteristics such as transmission routes (vertical, 
parenteral, and sexual), and the propensity to 
establish chronic infections which are often difficult 
to treat with currently available anti-viral agents 
(4,5,6). HIV/HBV co- infection is associated with 
increased liver related morbidity and mortality. The 
pathogenesis and clinical manifestations of both are  
due to the interaction of the virus and the host 
immune system (7). The immune system attacks 
hepatitis B virus and causes liver injury. Activated 
CD4+ and CD8+ lymphocytes recognize various 
HBV-derived peptides located on the surface of the 
hepatocytes, and an immunologic reaction occurs. 
Impaired immune reactions, (such as cytokine 
release, antibody production) or relatively tolerant 
immune status results in chronic hepatitis (8). The 
immune suppression caused by HIV infection 
accelerates the course of liver disease caused by 
chronic HBV infection and results in increased 
mortality compared to HIV monoinfected patients 
(9).  
 
Interferon does not appear to adversely affect the 
embryo or fetus. However, the data is limited, and 
the potential benefits of interferon use during 
pregnancy should clearly outweigh possible 
hazards (10, 11). Lamivudine used in combination 
with zidovudine caused pronounced and sustained 
increases in CD4-cell counts and reductions in HIV-
1 viral load in four separate studies, done in both 
previously antiretroviral untreated and pretreated 
HIV-1-positive patient Interestingly, lamivudine is 
also used to treat hepatitis B infections (12, 13). HBV 
replication has been proven to be inhibited by 
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lamivudine in 86.4% (95% CI, 75.7–93.6) of HIV-
HBV–coinfected patients (14, 15). Chronic HBV 
does not substantially alter the progression of HIV 
infection and does not influence HIV suppression 
or CD4+ cell responses following ART initiation 
(16,17). Initial data do not suggest that Lamivudine 
is teratogenic (18). Lamivudine has been used in the 
latter half of pregnancy in attempt to prevent 
perinatal transmission of hepatitis B virus infection 
with mixed success (19). Mother to child 
transmission of HIV and HBV occurs often either in 
utero or through exposure to blood or blood 
contaminated fluids at or around birth. Such 
perinatal transmission is believed to account for 35- 
50% of carriers (18). Perinatal childhood infection of 
HBV is characterised by symptomlessness, but 
places carriers at a high risk of developing chronic 
disease (3). It has also been shown that vertical 
transmission of hepatitis B virus occurs in about 
10% of neonates when the infection occur in the first 
trimester and in 60% to 90% of babies in the third 
trimester (20). Screening for HBsAg is routine in 
pregnancy in most developed countries, 122 
Colleges of Obstetrics and Gynecology worldwide 
screen pregnant women for Hepatitis (21, 22). In 
Nigeria, HIV is routinely tested for pregnant 
women but not HBV despite their overlapping 
routes of transmission. Sero-prevalence studies on 
HBsAg in Nigeria show that the prevalence of the 
infection in pregnant women range from 2-15% (23, 
24, 25).  
 
The prevalence of hepatitis B virus (HBV) infections 
in Nigeria have been reported as 17.1% among 
female sex workers in Nigeria and 11.9% in HIV 
infected persons (26, 27). Imade et al., had done a 
study in 2004 and reported a prevalence of 11.5% 
but did not check the immune status of the women 
in Jos and Oladokun et al., reported a prevalence 
rate of 8.9% co-infection rate among pregnant 
women in Ibadan (28, 29). This study was carried 
out to determine the prevalence of hepatitis B 
among HIV infected pregnant women in Jos and 
also to establish the effect of co-infection on their 
immunological status. 
MATERIALS AND METHODS 
Study Design 
A cross sectional study was carried out among HIV 
positive pregnant women at the Jos University 
Teaching Hospital (JUTH) and Plateau State 
Specialist Hospital (PSSH) between the months of 
May and June 2008. Blood samples were collected 
from one hundred and thirty five (135) of the 
subjects and Ethical clearance for this study was 
obtained from both the JUTH Institutional Health 
Research Ethical Committee and PSSH health 
research ethical committee. Patients were 
approached with a letter introducing the subject 
and their consent was obtained by the subject’s 
signature on the questionnaire given to them. 
Laboratory numbers was indicated on the 
questionnaires and same number on the sample 
bottle to protect patients’ identity. The outcome of 
this finding was referred to the clinician for extra 
attention and care. The samples were then tested for 
HBV surface antigens and CD4+ counts. 
 
Sample Collection 
A total of 135 blood samples  (The sample size was 
derived using the formula for sample size 
calculation: N = z2pq/d2 (where z = Standard 
normal deviation at 1.96 (which corresponds to 95% 
confidence interval; p = Prevalence of Hepatitis B 
surface antigen in ante-natal women in Nigeria 
from previous studies; q = 1-p; and d = degree of 
accuracy/ precision expected = 0.05). were collected 
from HIV positive pregnant women by 
venipuncture. 5mls of blood was collected 
aseptically and emptied into sterile vacutainer tubes 
and labelled. The uncoagulated blood was allowed 
to separate into serum at room temperature. 
 
Detection of HbsAG Using Antec Strips 
The serum was collected into clean containers and 
used to test for hepatitis B surface antigen HbsAg 
using the one step disposable Hepatitis B surface 
antigen test strips (Antec diagnostics; United 
Kingdom). The test procedure was carried out 
following manufacturer’s instructions and the 
results interpreted and recorded accordingly. 
 
Determination of Absolute CD4+ count  
The blood was placed on a mixer in order to get a 
homogenous mixture. All the test tubes were 
labeled accordingly. Monoclonal antibody PE, 20µl 
was pipetted into a tube; 20µl of the patient’s blood 
sample was added. The mixture was thoroughly 
mixed and incubated in the dark for 15 minutes. 
No-lyse phosphate buffered saline (PBS) dilution 
buffer, 800µl was added and the mixture connected 
to a cyflow counter (Partec, Germany) for analysis. 
 
CD4+ % Enumeration 
Monoclonal antibody CD4+ (CD4 MAb PE) and 
CD45+ (CD4 MAb PE), 10µl was pipette into rhoren 
tubes, 20µl of the patient’s blood samples was 
added. The mixture was thoroughly mixed and 
incubated in the dark for 15 minutes at room 
temperature. No-lyse dilution buffer 1 and 2, 400µl 
was added just before reading and connected to 
SL_3 cyflow (Partec, Germany) and analysed.  
 
Interpretation of Immunologic Status Result  
The CD4+count of normal patients (healthy 
immune competent, HIV negative persons in 
Nigeria) lie between 547-1327 cells/ mm3. Any 
CD4+ Count within the range 200 – 500 cells/mm3 
suggests that the person is immune compromised 










Out of the 135 sera collected from HIV infected 
pregnant women examined, 16 of them were 
seropositive for Hepatitis B representing 11.8% of 
the total (Table 1). Women between the age ranges 
36-40 had the highest rate of co-infection, this is not 
statistically significant ( χ2= 0.074, P=0.05 df=40.05), 
while women between the age range 16-20 had no 
co-infection (Table 1).  
 
Association of HIV/HBV co-infection in Pregnant 
Women and Treatment, Occupational and 
Educational Characteristics  
The occupation of the women examined showed 
that housewives and business women had higher 
rates of HIV/HBV co-infection (8.8% and 5.5% 
respectively), occupation is significantly associated 
with co-infection (χ2=0.035 P=0.05 df=4)  With 
respect to educational level,  pregnant women who 
were educated only to secondary level had the 
highest prevalence of co-infection (4.4%), those with 
no formal education had the lowest prevalence 
rates (0.7%) but the difference in the prevalence 
rates was not statistically significant in women with 
secondary education compared to the rest (χ2 = 
0.545 P= 0.05 df=3) (Table 2). Among the 135 
women examined 18.5% of those who had HIV 
alone were on antiretroviral therapy (ART) while 




TABLE 1; AGE RANGE AND PREVALENCE 
DISTRIBUTION OF HIV/HBV CO-INFECTED IN HIV 
POSITIVE PREGNANT WOMEN 
%= Percentage ; *= Number of pregnant women 
examined;  β= Number of pregnant women positive for 




The CD4+ counts of the women with HIV/HBV co-
infection were lower than those with HIV alone but 
there was no association between co-infection and 
the immunologic status of the pregnant women  
(χ2= 0.297 P =0.05 df=5). But 81.2% of the women 
with HIV/HBV co-infection had CD4+ values 
below 300 cells/mm3 (Table 3). 
 
TABLE.  2; TREATMENT, OCCUPATIONAL AND EDUCATIONAL CHARACTERISTICS OF HIV/HBV CO-INFECTED 
PREGNANT WOMEN IN JOS 
 










NON-ART 94 (69.6) 7 (5.2) 
             n=135   
   
Occupational Characteristics   
BUSINESS  7 (7.52) 5 (5.5) 
HOUSE WIFE  30 (33.0) 8 (8.8) 
SELF EMPLOYMENT  17 (18.7) 1 (1.1) 
CIVIL SERVANT  12 (13.1) 1 (1.1) 
PRIVATE ESTABLISHMENT  10 (11.0) 0 (0.0) 
   n=91 χ2 =0.035  P=0.05 df=4   
   
Educational Characteristics   
PRIMARY  24 (24.0) 5 (5.0) 
SECONDARY  30 (30.0) 6 (6.0) 
TERTIARY  29 (29.0) 4 (4.0) 
NO FORMAL EDUCATION  1  (1.0) 1  (1.0) 
      n= 100   χ2 =0.545  P=0.05 df=3   




















16-20 10 0 0.0  
21-25 31 1 0.7  
26-30 48 5 3.7  
31-35 28 4 3.0  
36-40 18 6 4.4  
TOTAL 135 16 11.8  
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HIV Positive HIV/HBV Co-infected 
0-100 16 11 5 
101-200 9 5 4 
201-300 13 9 4 
301-400 13 12 1 
401-500 4 3 1 
501-600 0 0 0 
601-700 1 0 1 
TOTAL 56* 40 16 
χ2 =0.297    P=0.05 df=0.05; n= 56; *=only 56 out of the total subjects sampled had their CD4+ counts determined 
 
DISCUSSION 
HBV infection in pregnancy is emerging as an 
increasingly important issue, although more 
attention has been given to HCV co-infection 
because of the higher possibility of  developing 
chronic disease,  HBV prevalence rates have been 
reported to be higher than HCV rates in Nigeria 
(31,32). In this study, 11.8% of the pregnant women 
population examined was found positive for 
HIV/HBV co-infection.  In 2004 the rates of 
HIV/HBV co-infection among pregnant women in 
Jos was reported as 11.5%, this rate is almost similar 
to that reported by this study, suggesting that the 
situation with HIV/HBV co-infection in our 
environment has not changed (33). 
 
Other Nigerian studies have reported different 
prevalence rates. In a study in the Federal Capital 
Teritory (FCT), Abuja, Nigeria the prevalence rate 
of HIV/HBV co-infection was reported as 7.1% , in 
Yola North East Nigeria, a prevalence rate of 8.2% 
was reported among pregnant women.  Adesina et 
al., reported a prevalence rate of 8.9% among HIV 
infected pregnant women (34, 35, 36). Similarly, in 
other parts of Africa, varying prevalence rates have 
been reported; Chasela reported a prevalence rate 
of 10.4% among pregnant women in Malawi, in 
Uganda 4.1% was reported among HIV positive 
pregnant women and a rate of 2.4% in Rwanda also 
among HIV infected pregnant women (37,38). In 
Europe, a prevalence rate of 4.9% has been reported 
among HIV infected pregnant women and a low co-
infection rate of 1.5% was reported among pregnant  
 
 
women in America (39,40). Jos is thus hyper-
endemic area for Hepatitis B virus infection, 
according to WHO classification for Hepatitis B 
endemicity (41,42).  
 
Age is not an important factor related to the 
prevalence of hepatitis B infection in HIV infected 
women as revealed in this study. The difference in 
HIV/HBV co-infection among the various age 
groups shows that women within the age range 36-
40 had higher prevalence rates of HIV/HBV co-
infection than women within other age brackets. 
Eke et al., and Habiba et al., however, reported 
higher prevalence rates in pregnant women within 
the age brackets of 20-24 and 25-35 years 
respectively (43,44). This deviation may have been 
due to the size of the population studied, a higher 
population size could change the dynamics.  
 
Occupation was found to be associated with the 
prevalence of co-infection, among house wives and 
business women. This is similar to the report of 
Mohammadi et al., who reported significant 
association between HIV/HBV co-infection among 
house wives compared to other occupations in Iran 
(45).  
 
Educational background was not associated with 
co-infection rates in our study ,  (P>0.05), and this 
was the observation of Eke et al. also, who reported 
no association between HBV infection and 
educational level among individuals in low 
resource settings in Nigeria (43). Ezegbudo et al., 
however found an association between educational 
background and HIV/HBV infection in pregnant 
women in Anambra state Nigeria (46). 
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With respect to the immune status of the study 
subjects, although the CD4+ counts of the women 
with co-infection were below 300 cells /mm3 there 
was no statistically significant association between 
HIV/HBV co-infection and the immune status of 
the pregnant women. Most studies have reported 
reduced CD4+ count in HIV/HBV co-infected 
women when compared with monoinfected 
women. Otegbayo et al., observed lower CD4+ 
counts in HIV/HBV co-infected pregnant women in 
Ibadan, Nigeria (27). Forbi et al., also reported a 
lower CD4+ count in patients with HIV/HBV co-
infection as compared with patients with HIV 
monoinfection, another study by Idoko et al., 
reported same in Jos (47,48). However Hoffman et 
al., (49) reported that HBV does not affect CD4+ cell 
count in people infected with HIV. 
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